(Floxuridine + irinotecan hydrochloride) is under clinical development by Luye Pharma Group and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase II drugs for Pancreatic Cancer have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how (Floxuridine + irinotecan hydrochloride)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

(Floxuridine + irinotecan hydrochloride) overview

A fixed-dose combination of irinotecan hydrochloride and floxuridine (LY01616) is under development for the treatment of colorectal cancer, gastric cancer, esophageal cancer, pancreatic cancer, small cell lung cancer, soft tissue sarcoma, cervical cancer and advanced solid tumor. It is a liposomal formulation and administered by intravenous route. Floxuridine acts by targeting thymidylate synthase and irinotecan hydrochloride acts by targeting DNA topoisomerase 1. The drug candidate is developed based on liposome platform.

Luye Pharma Group overview

Luye Pharma Group (Luye Pharma), a subsidiary of Luye Life Sciences Group Ltd, is a drug development company that discovers, manufactures, and commercializes novel formulations, generic drugs, and pharmaceutical products. The company offers its products in the form of tablets, formulations for injections, capsules, gels, anti-psychotic medicines, and modified-release dosages in the therapeutic areas of oncology, cardiovascular, orthopedics, hepatology, gastroenterology, gynecology, diabetes and central nervous system (CNS). Luye Pharma operates its R&D and manufacturing facilities in the US, China and Europe. The company exports products to Germany, the UK, Southeast Asia, the Middle East and North Africa. Luye Pharma is headquartered in Yantai, Shandong, China.

For a complete picture of (Floxuridine + irinotecan hydrochloride)’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.